| Followers | 145 |
| Posts | 27561 |
| Boards Moderated | 3 |
| Alias Born | 02/07/2004 |
Tuesday, September 08, 2020 11:49:42 AM
Sep. 8, 2020 10:30 AM ET|About: RedHill Biopharma Ltd. (RDHL)|By: Pranav Ghumatkar, SA News Editor
RedHill Biopharma (RDHL +12.0%) announces encouraging results from a preclinical study assessing protease inhibitor opaganib in an in vitro model of human lung bronchial tissue. Opaganib completely inhibited SARS-CoV-2 replication.
Opaganib is currently being evaluated in a global Phase 2/3 trial and a U.S. Phase 2 study in severely ill COVID-19 patients with pneumonia.
Opaganib demonstrated the most potent activity compared to all compounds tested, including the positive control, Gilead Sciences' (GILD -2.4%) remdesivir.
In addition to Opaganib, RedHill’s in-vitro study evaluated the antiviral activity of its Phase-2 stage investigational drug, RHB-107.
A U.S. Phase 2/3 study with RHB-107 in an outpatient setting should launch later this year.
You are most welcome, Scrapiron.
Recent RDHL News
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
